Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: A call for greater cognizance

Annals of Hepatology

Volumn 13, Issue 4, 2014, Pages 461-465

  Yang, Ju Dong ^a   Girotra, Mohit ^a   Restrepo, Alejandro ^b   Waheed, Sarah ^b   Barlogie, Bart ^b   Duarte Rojo, Andres ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Bone marrow transplant; Chemotherapy; Hematologic malignancy; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BORTEZOMIB; CARFILZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENTECAVIR; ETOPOSIDE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYPERTENSIVE AGENT; IMMUNOGLOBULIN KAPPA CHAIN; LAMIVUDINE; LENALIDOMIDE; MELPHALAN; MESNA; POMALIDOMIDE; PREDNISOLONE; TENOFOVIR; THALIDOMIDE; VINCRISTINE; VIRUS DNA; VORINOSTAT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CASE REPORT; DEATH; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; HEPATITIS B; HOSPITAL READMISSION; HUMAN; HYPOTENSION; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; MALE; MEDICATION COMPLIANCE; METABOLIC ACIDOSIS; MIDDLE AGED; MULTIPLE MYELOMA; PATIENT COMPLIANCE; PULMONARY HYPERTENSION; SEROCONVERSION; STAPHYLOCOCCAL BACTEREMIA; VIRUS REACTIVATION; BLOOD; GENETICS; HEPATITIS B VIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

AGED; ANTINEOPLASTIC AGENTS; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

EID: 84902386802     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30855-5     Document Type: Article

References (19)

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49: S156-S165.
2. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.
3. Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study. World J Gastroenterol 2013; 19: 923-30.
4. Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012; 91: 1007-12.
5. Park S, Kim K, Kim DH, Jang JH, Kim SJ, Kim WS, Jung CW, et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol Blood Marrow Transplant 2011; 17: 1630-7.
6. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, Cheung M, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-9.
7. Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol 2010; 17: 32-8.
8. Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011; 7: 141-7.
9. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
10. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-80.
11. Tanaka H, Sakuma I, Hashimoto S, Takeda Y, Sakai S, Takagi T, Shimura T, et al. Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report. J Clin Exp Hematop 2012; 52: 67-9.
12. Yoshida T, Kusumoto S, Inagaki A, Mori F, Ito A, Ri M, Ishida T, et al. Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. Int J Hematol 2010; 91: 844-9.
13. Mya DH, Han ST, Linn YC, Hwang WY, Goh YT, Tan DC. Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Ann Oncol 2012; 23: 421-6.
14. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010; 28: 3199-202.
15. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
16. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012; 156: 743-5.
17. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57: 1-20.
18. Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012; 30: 3167-73.
19. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202: 192-201.